Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Urological Manifestations

ClinicalTrials.gov lists 3,103 trials for Urological Manifestations or a narrower condition beneath it. Astellas Pharma Inc has the most among industry and government lead sponsors, with 50.

MeSH D020924 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 113 Phase 1/2 Phase 1/2 37 Phase 2 Phase 2 248 Phase 2/3 Phase 2/3 41 Phase 3 Phase 3 263 Phase 4 Phase 4 324 Not applicable Not applicable 1,380 Observational Observational 695 Phase 1 Phase 1 113 Phase 1/2 Phase 1/2 37 Phase 2 Phase 2 248 Phase 2/3 Phase 2/3 41 Phase 3 Phase 3 263 Phase 4 Phase 4 324 Not applicable Not applicable 1,380 Observational Observational 695

Trials per phase (log scale)

1 more section with rows

13 of the 3,103 trials are tagged with Urological Manifestations itself; the rest are tagged with a narrower condition beneath it.

Get the Urological Manifestations report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Urological Manifestations trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 190

1993: 1 trials (Observational 1) 1994: 2 trials (Observational 2) 1995: 2 trials (Phase 3 2) 1996: 6 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 2) 1997: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 1998: 3 trials (Not applicable 2, Phase 4 1) 1999: 3 trials (Phase 3 1, Phase 2 2) 2000: 7 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 1, Phase 1/2 1) 2001: 15 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 6, Phase 2 3) 2002: 20 trials (Observational 3, Not applicable 3, Phase 4 3, Phase 3 5, Phase 2/3 2, Phase 2 3, Phase 1 1) 2003: 27 trials (Observational 1, Not applicable 5, Phase 4 3, Phase 3 15, Phase 2 2, Phase 1/2 1) 2004: 49 trials (Observational 5, Not applicable 13, Phase 4 10, Phase 3 14, Phase 2/3 1, Phase 2 5, Phase 1/2 1) 2005: 62 trials (Observational 8, Not applicable 21, Phase 4 15, Phase 3 6, Phase 2/3 1, Phase 2 10, Phase 1/2 1) 2006: 70 trials (Observational 13, Not applicable 16, Phase 4 15, Phase 3 9, Phase 2/3 2, Phase 2 11, Phase 1/2 2, Phase 1 2) 2007: 96 trials (Observational 17, Not applicable 16, Phase 4 17, Phase 3 17, Phase 2/3 3, Phase 2 19, Phase 1 7) 2008: 100 trials (Observational 22, Not applicable 23, Phase 4 21, Phase 3 13, Phase 2/3 3, Phase 2 9, Phase 1/2 1, Phase 1 8) 2009: 121 trials (Observational 28, Not applicable 25, Phase 4 31, Phase 3 17, Phase 2 10, Phase 1/2 2, Phase 1 8) 2010: 93 trials (Observational 26, Not applicable 22, Phase 4 14, Phase 3 12, Phase 2/3 4, Phase 2 11, Phase 1/2 1, Phase 1 3) 2011: 88 trials (Observational 24, Not applicable 16, Phase 4 19, Phase 3 8, Phase 2/3 2, Phase 2 11, Phase 1/2 2, Phase 1 6) 2012: 119 trials (Observational 32, Not applicable 34, Phase 4 17, Phase 3 12, Phase 2/3 1, Phase 2 13, Phase 1/2 2, Phase 1 8) 2013: 115 trials (Observational 20, Not applicable 41, Phase 4 10, Phase 3 18, Phase 2/3 1, Phase 2 16, Phase 1/2 5, Phase 1 4) 2014: 132 trials (Observational 36, Not applicable 60, Phase 4 15, Phase 3 10, Phase 2/3 2, Phase 2 3, Phase 1/2 1, Phase 1 5) 2015: 131 trials (Observational 28, Not applicable 56, Phase 4 13, Phase 3 10, Phase 2/3 4, Phase 2 6, Phase 1/2 4, Phase 1 10) 2016: 131 trials (Other 1, Observational 23, Not applicable 52, Phase 4 12, Phase 3 17, Phase 2/3 3, Phase 2 12, Phase 1/2 2, Phase 1 9) 2017: 151 trials (Observational 45, Not applicable 73, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 13, Phase 1/2 1, Phase 1 8) 2018: 159 trials (Observational 34, Not applicable 80, Phase 4 12, Phase 3 11, Phase 2/3 1, Phase 2 17, Phase 1/2 2, Phase 1 2) 2019: 172 trials (Observational 45, Not applicable 95, Phase 4 10, Phase 3 5, Phase 2/3 2, Phase 2 10, Phase 1/2 1, Phase 1 4) 2020: 133 trials (Other 1, Observational 28, Not applicable 75, Phase 4 7, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 9) 2021: 175 trials (Observational 45, Not applicable 99, Phase 4 11, Phase 3 6, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 5) 2022: 181 trials (Observational 40, Not applicable 107, Phase 4 14, Phase 3 7, Phase 2 7, Phase 1/2 2, Phase 1 4) 2023: 182 trials (Observational 34, Not applicable 123, Phase 4 8, Phase 3 5, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 3) 2024: 167 trials (Observational 40, Not applicable 100, Phase 4 9, Phase 3 3, Phase 2 12, Phase 1/2 1, Phase 1 2) 2025: 190 trials (Observational 41, Not applicable 119, Phase 4 11, Phase 3 8, Phase 2/3 2, Phase 2 6, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 181
2025 190
2024 167
2023 182
2022 181
2021 175
2020 133
2019 172
2018 159
2017 151

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 210 trials starting in 2026 and about 200 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 34 months from start to primary completion across 237 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 1,967 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Urological Manifestations trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 113
Phase 1/2 37
Phase 2 248
Phase 2/3 41
Phase 3 263
Phase 4 324
Not applicable 1,380
Observational 695
Unknown 2

How many Urological Manifestations trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 149
Recruiting 282
Enrolling by invitation 28
Active, not recruiting 94
Completed 1,793

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Urological Manifestations trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Astellas Pharma Inc 50
Pfizer 36
Allergan 30
Coloplast A/S 20
Ferring Pharmaceuticals 20

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Urological Manifestations? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Tolterodine 53
Tamsulosin 36
Duloxetine 18
Darifenacin 16
BMS-512148 15

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Solifenacin PO 92
mirabegron OCAS 80
type A botulinum toxin 55
Fesoterodine ER (fasted) 39
Desmopresin 21

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Urological Manifestations trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 193 58
Osteoarthritis 125 34
Urinary tract infection 100 35
Angina Unstable 86 3
Acute myocardial infarction 82 18

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages